

# Jinsong Hu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3551699/publications.pdf>

Version: 2024-02-01

32  
papers

1,431  
citations

430442

18  
h-index

433756

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2981  
citing authors

#	ARTICLE	IF	CITATIONS
1	Evaluation of prognostic staging systems of multiple myeloma in the era of novel agents. <i>Hematological Oncology</i> , 2022, 40, 212-222.	0.8	3
2	Frontline Science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. <i>Journal of Leukocyte Biology</i> , 2021, 109, 13-22.	1.5	241
3	Resistance of osteosarcoma cells to the proapoptotic effects of carfilzomib involves activation of mitogen activated protein kinase pathways. <i>Experimental Physiology</i> , 2021, 106, 438-449.	0.9	4
4	Leptin correlates with monocytes activation and severe condition in COVID-19 patients. <i>Journal of Leukocyte Biology</i> , 2021, 110, 9-20.	1.5	63
5	PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib. <i>Frontiers in Oncology</i> , 2021, 11, 684232.	1.3	3
6	Comprehensive Analysis of m6A RNA Methylation Regulators in the Prognosis and Immune Microenvironment of Multiple Myeloma. <i>Frontiers in Oncology</i> , 2021, 11, 731957.	1.3	4
7	ER stress arm XBP1s plays a pivotal role in proteasome inhibition-induced bone formation. <i>Stem Cell Research and Therapy</i> , 2020, 11, 516.	2.4	25
8	Hypoxia Impairs NK Cell Cytotoxicity through SHP-1-Mediated Attenuation of STAT3 and ERK Signaling Pathways. <i>Journal of Immunology Research</i> , 2020, 2020, 1-14.	0.9	31
9	The phenotypic changes of $\hat{\text{T}}$ T cells in COVID-19 patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 11603-11606.	1.6	54
10	Naturally activated adaptive immunity in COVID-19 patients. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 12457-12463.	1.6	21
11	A novel CD2 staining-based flow cytometric assay for assessment of natural killer cell cytotoxicity. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23519.	0.9	2
12	Oncostatin M upregulates Livin to promote keratinocyte proliferation and survival via ERK and STAT3 signalling pathways. <i>Experimental Physiology</i> , 2020, 105, 1151-1158.	0.9	10
13	IGF-1 promotes multiple myeloma progression through PI3K/Akt-mediated epithelial-mesenchymal transition. <i>Life Sciences</i> , 2020, 249, 117503.	2.0	22
14	Cell cycle exit during bortezomib-induced osteogenic differentiation of mesenchymal stem cells was mediated by Xbp1s-upregulated p21 <sup>Cip1</sup> and p27 <sup>Kip1</sup> . <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 9428-9438.	1.6	13
15	Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma. <i>Cell Stress and Chaperones</i> , 2020, 25, 357-367.	1.2	21
16	Identification of a Five-CpG Signature with Diagnostic Value in Thyroid Cancer. <i>Journal of Computational Biology</i> , 2019, 26, 1409-1417.	0.8	2
17	Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-1 <sup>2</sup> axis. <i>Biochemical and Biophysical Research Communications</i> , 2019, 512, 360-366.	1.0	30
18	Methylphenidate ameliorates hypoxia-induced mitochondrial damage in human neuroblastoma SH-SY5Y cells through inhibition of oxidative stress. <i>Life Sciences</i> , 2018, 197, 40-45.	2.0	9

#	ARTICLE	IF	CITATIONS
19	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, <i>In Vivo</i> and <i>In Vitro</i> . <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1763-1773.	1.9	48
20	The Role of Notch Signaling in Multiple Myeloma. , 2013, , 77-95.		1
21	Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM-cell proliferation. <i>Leukemia</i> , 2012, 26, 1402-1405.	3.3	42
22	Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 763-771.	1.2	51
23	Activation of ATF4 mediates unwanted Mcl-1 accumulation by proteasome inhibition. <i>Blood</i> , 2012, 119, 826-837.	0.6	78
24	Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma. <i>Biochemical and Biophysical Research Communications</i> , 2012, 428, 518-524.	1.0	47
25	Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. <i>Leukemia</i> , 2012, 26, 2546-2549.	3.3	45
26	Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. <i>Blood</i> , 2012, 119, 5782-5794.	0.6	268
27	Syntheses of N-sulfonyl-N,N-disubstituted amidines via a three-component free-radical coupling reaction of tertiary amines and arenesulfonyl azides with terminal alkynes. <i>Science China Chemistry</i> , 2012, 55, 214-222.	4.2	17
28	Mcl-1 Reduction Due to Caspase-dependent Cleavage during Endoplasmic Reticulum Stress-induced Apoptosis. <i>Journal of Biological Chemistry</i> , 2011, 286, 1e24.	1.6	4
29	Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. <i>Blood</i> , 2010, 116, 1524-1527.	0.6	131
30	Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 2132-2143.	1.6	29
31	Involvement of Dll1/Notch Interaction In MM Drug Resistance, Clonogenic Growth and In Vivo Engraftment. <i>Blood</i> , 2010, 116, 2966-2966.	0.6	0
32	CD167 Acts as a Novel Costimulatory Receptor in T-Cell Activation. <i>Journal of Immunotherapy</i> , 2009, 32, 773-784.	1.2	8